Gallstone dissolution therapy with ursodiol

1989 ◽  
Vol 34 (S12) ◽  
pp. S39-S43 ◽  
Author(s):  
Gerald Salen
Digestion ◽  
1986 ◽  
Vol 34 (1) ◽  
pp. 51-59 ◽  
Author(s):  
M. Neubrand ◽  
T. Sauerbruch ◽  
F. Stellaard ◽  
G. Paumgartner

1985 ◽  
Vol 74 (12) ◽  
pp. 1344
Author(s):  
Bob D. Rush ◽  
Mary J. Ruwart ◽  
Bradley D. Anderson ◽  
William I. Higuchi

1992 ◽  
Vol 37 (4) ◽  
pp. 628-630 ◽  
Author(s):  
Joseph P. M. Ellul ◽  
Richard Groves ◽  
Julian R. F. Walters ◽  
Gerard M. Murphy

1981 ◽  
Vol 70 (6) ◽  
pp. 713-715 ◽  
Author(s):  
C.C. Su ◽  
J.Y. Park ◽  
W.I. Higuchi ◽  
M.H. Alkan ◽  
O.I. Corrigan ◽  
...  

1988 ◽  
Vol 5 (03) ◽  
pp. 186-194 ◽  
Author(s):  
Claire Bender ◽  
Hugh Williams

Endoscopy ◽  
1990 ◽  
Vol 22 (04) ◽  
pp. 176-179 ◽  
Author(s):  
N. Soehendra ◽  
H. Schulz ◽  
V. Ch. Nam ◽  
A. Maydeo ◽  
J. P. Schenkengel ◽  
...  

1985 ◽  
Vol 23 (19) ◽  
pp. 75-76

Rowachol (Tillotts) is a mixture of monoterpenes intended for the dissolution of cholesterol gallstones, as an adjunct to the existing drugs chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) whose use we discussed last month.1 When combined with CDCA, Rowachol is claimed to dissolve stones in the common duct. This article assesses its efficacy both alone and in combination therapy.


Sign in / Sign up

Export Citation Format

Share Document